Scancell Holdings Plc Change of Nominated Advisor
June 21 2024 - 2:00AM
RNS Regulatory News
RNS Number : 3032T
Scancell Holdings Plc
21 June 2024
21 June 2024
Scancell Holdings plc
("Scancell" or the "Company")
Change of Nominated
Advisor
Scancell Holdings plc (AIM: SCLP), the developer of
novel immunotherapies for the treatment of cancer, is pleased to
announce that Panmure Gordon (UK) Limited has been appointed as the
Company's Nominated Advisor with immediate effect and will continue
as Joint Broker.
This announcement contains insider information for
the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)
|
For further
information, please contact:
|
|
|
|
|
|
Scancell Holdings
plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
|
|
|
Panmure Gordon (UK)
Limited (Nominated Advisor and Joint Broker)
|
|
|
Emma Earl, Freddy Crossley, Will Goode, Mark
Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)
|
|
|
|
|
|
WG Partners LLP
(Joint Broker)
|
+44(0) 20 3705 9330
|
|
David Wilson/Claes Spang/Satheesh
Nadarajah/Erland Sternby
|
|
|
|
|
|
ICR
Consilium
|
+44 (0) 20 3709 5700
|
|
Mary-Jane Elliott/Angela Gray/Lindsey
Neville
|
scancell@consilium-comms.com
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer. The Company is building a pipeline of
innovative products by utilising its four technology platforms:
Moditope® and
ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and
ImmunoBody®) this includes
citrullination and homocitrullination of proteins, whereas its mAb
portfolio targets glycans or sugars that are added onto proteins
and / or lipids (GlyMab®) or enhances the potency of
antibodies and their ability to directly kill tumour cells
(AvidiMab®).
For further information about Scancell, please visit:
https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
APPFMMBTMTBTTLI
Scancell (LSE:SCLP)
Historical Stock Chart
From Dec 2024 to Jan 2025
Scancell (LSE:SCLP)
Historical Stock Chart
From Jan 2024 to Jan 2025
